Toronto Dominion Bank
ALXN

Toronto Dominion Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Toronto Dominion Bank’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-573,820
Closed -$105M – 1551
2021
Q2 		$105M Buy
573,820
+216,160
+60% +$37.1M 0.16% 85
2021
Q1 		$54.7M Buy
357,660
+220,392
+161% +$34.1M 0.1% 138
2020
Q4 		$21.4M Sell
137,268
-252,104
-65% -$32.4M 0.04% 265
2020
Q3 		$44.6M Buy
389,372
+243,792
+167% +$26.3M 0.11% 130
2020
Q2 		$16.3M Sell
145,580
-22,007
-13% -$2.34M 0.04% 299
2020
Q1 		$15M Sell
167,587
-39,599
-19% -$3.89M 0.05% 266
2019
Q4 		$22.4M Buy
207,186
+40,497
+24% +$4.33M 0.04% 283
2019
Q3 		$16.3M Sell
166,689
-151,791
-48% -$17.1M 0.03% 340
2019
Q2 		$20.9M Buy
318,480
+162,731
+104% +$21M 0.04% 278
2019
Q1 		$21M Buy
155,749
+22,041
+16% +$2.74M 0.03% 300
2018
Q4 		$13M Sell
133,708
-11,589
-8% -$1.37M 0.02% 341
2018
Q3 		$20.2M Sell
145,297
-3,756
-3% -$471K 0.04% 277
2018
Q2 		$18.5M Buy
149,053
+29,437
+25% +$3.44M 0.04% 292
2018
Q1 		$13.3M Buy
119,616
+23,394
+24% +$2.8M 0.03% 333
2017
Q4 		$11.5M Buy
96,222
+11,505
+14% +$1.4M 0.03% 303
2017
Q3 		$11.9M Buy
84,717
+8,646
+11% +$1.17M 0.04% 261
2017
Q2 		$9.25M Buy
76,071
+15,464
+26% +$1.8M 0.03% 295
2017
Q1 		$7.35M Buy
60,607
+21,938
+57% +$2.83M 0.02% 316
2016
Q4 		$4.73M Buy
38,669
+32,122
+491% +$3.93M 0.01% 314
2016
Q3 		$802K Buy
6,547
+5,308
+428% +$683K ﹤0.01% 475
2016
Q2 		$145K Sell
1,239
-490
-28% -$69.5K ﹤0.01% 629
2016
Q1 		$241K Sell
1,729
-5,178
-75% -$760K ﹤0.01% 511
2015
Q4 		$1.32M Sell
6,907
-294
-4% -$51.4K 0.01% 309
2015
Q3 		$1.13M Buy
7,201
+1,023
+17% +$187K 0.01% 319
2015
Q2 		$1.12M Buy
6,178
+618
+11% +$107K 0.01% 367
2015
Q1 		$964K Sell
5,560
-2,621
-32% -$474K ﹤0.01% 373
2014
Q4 		$1.51M Buy
8,181
+4,447
+119% +$824K 0.01% 327
2014
Q3 		$619K Buy
3,734
+3
+0.1% +$493 ﹤0.01% 414
2014
Q2 		$583K Buy
3,731
+573
+18% +$90.5K ﹤0.01% 465
2014
Q1 		$480K Buy
3,158
+29
+0.9% +$4.61K ﹤0.01% 499
2013
Q4 		$416K Buy
+3,129
New +$376K ﹤0.01% 490

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Toronto Dominion Bank's ALXN Position: Q3 2021 in Review

Toronto Dominion Bank sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 573,820 shares — an estimated $105M sold.

Toronto Dominion Bank first reported a position in ALXN in Q4 2013 and held it in 31 quarters. The position peaked at $105M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Toronto Dominion Bank reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Toronto Dominion Bank sold 573,820 Alexion Pharmaceuticals shares in Q3 2021, an estimated $105M.
  • Toronto Dominion Bank first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 31 quarters.
  • Toronto Dominion Bank's Alexion Pharmaceuticals position peaked at $105M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Toronto Dominion Bank's 13F filing for Q3 2021, filed 8 Nov 2021.